Genetic polymorphisms and head and neck cancer risk (Review)

International Journal of Oncology

Volumn 32, Issue 5, 2008, Pages 945-973

  Hiyama, Toru ^a   Yoshihara, Masaharu ^a   Tanaka, Shinji ^b   Chayama, Kazuaki ^c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Genetic polymorphism; Head and neck cancer; Review; Risk

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ALDEHYDE DEHYDROGENASE ISOENZYME 2; CYTOCHROME P450 1A1; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE 1; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; HISTIDINE; PROLINE; PROTEIN P53; TYROSINE; UNCLASSIFIED DRUG; XRCC1 PROTEIN; TUMOR MARKER;

ASIAN; CANCER RISK; CARCINOGENESIS; CAUCASIAN; CODON; ENVIRONMENTAL FACTOR; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HEAD AND NECK CANCER; HIGH RISK POPULATION; HUMAN; MEDICAL LITERATURE; MEDLINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HEAD AND NECK TUMOR; META ANALYSIS;

GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HUMANS; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 45849105603     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.5.945     Document Type: Review

References (274)

1. Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin 49: 33-64, 1999.
2. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54: 8-29, 2004.
3. Yun HJ, Bogaerts J, Awada A and Lacombe D: Clinical trial design limitations in head and neck squamous cell carcinomas. Curr Opin Oncol 19: 210-215, 2007.
4. Hiyama T, Sato T, Yoshino K, Tsukuma H, Hanai A and Fujimoto I: Second primary cancer following laryngeal cancer with special reference to smoking habits. Jpn J Cancer Res 83: 334-339, 1992.
5. Geisler SA and Olshan AF: GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a mini-HuGE review. Am J Epidemiol 154: 95-105, 2001.
6. Zeka A, Gore R and Kriebel D: Effects of alcohol and tobacco on aerodigestive cancer risks: a meta-regression analysis. Cancer Causes Control 14: 897-906, 2003.
7. Bartsch H, Nair U, Risch A, Rojas M, Wikman H and Alexandrov K: Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tabacco-related cancers. Cancer Epidemiol Biomarkers Prev 9: 3-28, 2000.
8. Yokoyama A and Omori T: Genetic polymorphisms of alcohol and aldehyde dehydrogenases and risk for esophageal and head and neck cancers. Alcohol 35: 175-185, 2005.
9. Lazarus P and Park JY: Metabolizing enzyme genotype and risk for upper aerodigestive tract cancer. Oral Oncol 36: 421-431, 2000.
10. Hiyama T, Yoshihara M, Tanaka S and Chayama K: Genetic polymorphisms and esophageal cancer risk. Int J Cancer 121: 1643-1658, 2007.
11. Hiyama T, Tanaka S, Kitadai Y, et al: p53 codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer 100: 304-308, 2002.
12. Hiyama T, Yokozaki H, Kitadai Y, Haruma K, Yasui W, Kajiyama G and Tahara E: Overexpression of human telomerase RNA is an early event in oesophageal carcinogenesis. Virchows Arch 434: 483-487, 1999.
13. Hiyama T, Haruma K, Kitadai Y, et al: K-ras mutation in Helicobacter pylori-associated chronic gastritis in patients with and without gastric cancer. Int J Cancer 97: 562-566, 2002.
14. Park JY, Muscat JE, Ren Q, et al: CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomarkers Prev 6: 791-797, 1997.
15. Matthias C, Bockmuhl U, Jahnke V, et al: Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics 8: 91-100, 1998.
16. Oude Ophuis MB, van Lieshout EMM, Roelofs HMJ, Peters WHM and Manni JJ: Glutathione S-transferase M1 and T1 and cytochrome P4501A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions. Cancer 82: 936-943, 1998.
17. Katoh T, Kaneko S, Kohshi K, et al: Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer 83: 606-609, 1999.
18. Morita S, Yano M, Tsujinaka T, et al: Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer 80: 685-688, 1999.
19. Sato M, Sato T, Izumo T and Amagasa T: Genetically high susceptibity to oral squamous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes. Oral Oncol 36: 267-271, 2000.
20. Olshan AF, Weissler MC, Watson MA and Bell DA: GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 9: 185-191, 2000.
21. McWilliams JE, Evans AJ, Beer TM, Andersen PE, Cohen JI, Everts EC and Henner WD: Genetic polymorphisms in head and neck cancer risk. Head Neck 22: 609-617, 2000.
22. Sreelekha TT, Ramadas K, Pandey M, Thomas G, Nalinakumari KR and Pillai MR: Genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol 37: 593-598, 2001.
23. Hahn M, Hagedorn G, Kuhlisch E, Schackert HK and Eckelt U: Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol 38: 486-490, 2002.
24. Varzim G, Monteiro E, Silva RA, Fernandes J and Lopes C: CYP1A1 and XRCC1 gene polymorphisms in SCC of the larynx. Eur J Cancer Prev 12: 495-499, 2003.
25. Evans AJ, Henner WD, Eilers KM, et al: Polymorphisms of GSTT1 and related genes in head and neck cancer risk. Head Neck 26: 63-70, 2004.
26. Xie H, Hou L, Shields PG, et al: Metabolic polymorphisms, smoking, and oral cancer in Puerto Rico. Oncol Res 14: 315-320, 2004.
27. Marques CFS, Koifman S, Koifman RJ, Boffetta P, Brennan P and Hatagima A: Influence of CYP1A1, CYP2E1, GSTM3, and NAT2 genetic polymorphisms in oral cancer susceptibity: results from a case-control study in Rid de Janeiro. Oral Oncol 42: 632-637, 2006.
28. Sugimura T, Kumimoto H, Tohnai I, et al: Gene-environment interaction involved in oral carcinogenesis: molecular epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med 35: 11-18, 2006.
29. Tanimoto K, Hayashi S, Yoshiga K and Ichikawa T: Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose. Oral Oncol 35: 191-196, 1999.
30. Sato M, Sato T, Izumo T and Amagasa T: Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis 20: 1927-1931, 1999.
31. Ko Y, Abel J, Harth V, et al: Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 61: 4398-4404, 2001.
32. Kao SY, Wu CH, Lin SC, et al: Genetic polymorphism of cytochrome P4501A1 and susceptibility to oral squamous cell carcinoma and oral precancerous lesions associated with smoking/betel use. J Oral Pathol Med 31: 505-511, 2002.
33. Cheng YJ, Chien YC, Hildesheim A, et al: No association between genetic polymorphisms of CYP1A1, GSTM1, GSTT1, GSTP1, NAT2, and nasopharyngeal carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev 12: 179-180, 2003.
34. Gronau S, Jerg DKGM and Riechelmann H: Gene polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer? Otolaryngol Head Neck Surg 128: 674-680, 2003.
35. Gattas GJF, De Carvalho MB, Siraque MS, Curioni OA, Kohler P, Eluf-Neto J and Wunsch-Filho V: Genetic polymorphisms of CYP1A1, CYP2E1, GSTM1, and GSTT1 associated with head and neck cancer. Head Neck 28: 819-826, 2006.
36. Cha IH, Park JY, Chung WY, Choi MA, Kim HJ and Park KK: Polymorphisms of CYP1A1 and GSTM1 genes and susceptibility to oral cancer. Yonsei Med J 48: 233-239, 2007.
37. Boccia S, Cadoni G, Sayed-Tabatabaei FA, et al: CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer. J Cancer Res Clin Oncol 134: 93-100, 2007.
38. Li G, Liu Z, Sturgis EM, Chamberlain RM, Spitz MR and Wei Q: CYP2E1 G1532C, NQO1 Pro187Ser, and CYP1B1 Va1432Leu polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 14: 1034-1036, 2005.
39. Hildesheim A, Chen CJ, Caporaso NE, et al: Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan. Cancer Epidemiol Biomarkers Prev 4: 607-610, 1995.
40. Hung HC, Chuang J, Chien YC, et al: Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmenal factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev 6: 901-905, 1997.
41. Hildesheim A, Anderson LM, Chen CJ, et al: CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 89: 1207-1212, 1997.
42. Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, Suarez C and Coto E: Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P4501ID6 in the susceptibility to head and neck cancer. J Clin Pathol 51: 294-298, 1998.
43. Bouchardy C, Hirvonen A, Coutelle C, Ward PJ, Dayer P and Benhamou S: Role of alcohol dehydrogenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int J Cancer 87: 734-740, 2000.
44. Kongruttanachok N, Sukdikul S, Setavarin S, et al: Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: a correlative study. BMC Cancer 1: 4, 2001.
45. Liu S, Park JY, Schantz SP, Stern JC and Lazarus P: Elucidation of CYP2E1 5′ regulatory Rsal/PstI allelic variants and their role in risk for oral cancer. Oral Oncol 37: 437-445, 2001.
46. Neuhaus T, Ko YD, Lorenzen K, et al: Association of cytochrome P450 2E1 polymorphisms and head and neck squamous cell cancer. Toxicol Lett 151: 273-282, 2004.
47. Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W and Szyfter K: CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res 574: 112-123, 2005.
48. Yang XR, Diehl S, Pfeiffer R, et al: Evaluation of risk factors for nasopharyngeal carcinoma in high-risk nasopharyngeal carcinoma families in Taiwan. Cancer Epidemiol Biomarkers Prev 14: 900-905, 2005.
49. Worrall SE, Corrigan M, High A, et al: Susceptibility and outcome in oral cancer: preliminary data showing an association with polymorphism in cytochrome P450 CYP2D6. Pharmacogenetics 8: 433-439, 1998.
50. Topic E, Stefanovic M, Nikolic V, Zoricic I, Ivanisevic AM and Zuntar I: Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism. Clin Chem Lab Med 36: 655-658, 1998.
51. Topic E, Stefanovic M, Ivanisevic AM, Petrinovic R and Curcic I: The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients. Clin Chim Acta 296: 101-109, 2000.
52. Topcu Z, Chiba I, Fujieda M, et al: CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. Carcinogenesis 23: 595-598, 2002.
53. Tiwawech D, Srivatanakul P, Karalak A and Ishida T: Cytochrome P450 2A6 polymorphism in nasopharyngeal carcinoma. Cancer Lett 241: 135-141, 2006.
54. Chen WC, Tsai MH, Wan L, Chen WC, Tsai CH and Tsai FJ: CYP17 and tumor necrosis factor-α gene polymorphisms are associated with risk of oral cancer in Chinese patients in Taiwan. Acta Otolaryngol 125: 96-99, 2005.
55. Trizna Z, Clayman GL, Spitz MR, Briggs KL and Goepfert H: Glutathione S-transferase genotypes as risk factors for head and neck cancer. Am J Surg 170: 499-501, 1995.
56. Jahnke V, Matthias C, Fryer A and Strange R: Glutathione S-transferase and cytochrome-P450 polymorphism as risk factors for squamous cell carcinoma of the larynx. Am J Surg 172: 671-673, 1996.
57. Deakin M, Elder J, Hendrickse C, et al: Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 17: 881-884, 1996.
58. Coutelle C, Ward PJ, Fleury B, et al: Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. Hum Genet 99: 319-325, 1997.
59. Kihara M, Kihara M, Kubota A, Furukawa M and Kimura H: GSTM1 gene polymorphism as a possible marker for susceptibility to head and neck cancers among Japanese smokers. Cancer Lett 112: 257-262, 1997.
60. Jaskula-Sztul R, Reinikainen M, Husgafvel-Pursiainen K, Szmeja Z, Szyfter W, Szyfter K and Hirvonen A: Glutathione S-transferase M1 and T1 genotypes and susceptibility to smoking related larynx cancer. Biomarkers 3: 149-155, 1998.
61. Jourenkova N, Reinikainen M, Bouchardy C, Dayer P, Benhamou S and Hirvonen A: Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev 7: 19-23, 1998.
62. Lafuente A, Maristany M, Arias C, et al: Glutathione and glutathione S-transferase in human squamous cell carcinomas of the larynx and GSTM1 dependent risk. Anticancer Res 18: 107-111, 1998.
63. Jourenkova-Mironova N, Voho A, Bouchardy C, Wikman H, Dayer P, Benhamou S and Hirvonen A: Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Int J Cancer 81: 44-48, 1999.
64. Cheng L, Sturgis EM, Eicher SA, Char D, Spitz MR and Wei Q: Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. Int J Cancer 84: 220-224, 1999.
65. Nazar-Stewart V, Vaughan TL, Burt RD, Chen C, Berwick M and Swanson GM: Glutathione S-transferase M1 and susceptibility to nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 8: 547-551, 1999.
66. Nomura T, Noma H, Shibahara T, Yokoyama A, Muramatusu T and Ohmori T: Aldehyde dehydrogenase 2 and glutathione S-transferase M1 polymorphisms in relation to the risk for oral cancer in Japanese drinkers. Oral Oncol 36: 42-46, 2000.
67. Park JY, Muscat JE, Kaur T, Schantz SP, Stern JC, Richie JP Jr and Lazarus P: Comparison of GSTM polymorphisms and risk for oral cancer between African-Americans and Caucasians. Pharmacogenetics 10: 123-131, 2000.
68. Hong YJ, Lee JK, Lee GH and Hong SI: Influence of glutathione S-transferase MI and T1 genotypes on larynx cancer risk among Korean smokers. Clin Chem Lab Med 38: 917-919, 2000.
69. Cabelguenne A, Loriot MA, Stucker I, et al: Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer 93: 725-730, 2001.
70. Hanna E, MacLeod S, Vural E and Lang N: Genetic deletions of glutathione-S-transferase as a risk factor in squamous cell carcinoma of the larynx: a preliminary report. Am J Otolaryngol 22: 121-123, 2001.
71. Kietthubthew S, Sriplung H and Au WW: Genetic and environmental interactions on oral cancer in Southern Thailand. Environ Mol Mutagen 37: 111-116, 2001.
72. Buch SC, Notani PN and Bhisey RA: Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis 23: 803-807, 2002.
73. To-Figueras J, Gene M, Gomez-Catalan J, et al: Microsomal epoxide hydrolase and glutathione S-transferase polymorphisms in relation to laryngeal carcinoma risk. Cancer Lett 187: 95-101, 2002.
74. Bardakci F, Canbay E, Degerli N, Coban L and Canbay EI: Relationship of tobacco smoking with GSTM1 gene polymorphism in laryngeal cancer. J Cell Mol Med 7: 307-312, 2003.
75. Risch A, Ramroth H, Raedts V, et al: Laryngeal cancer risk in Caucasians is associated with alcohol and tobacco consumption but not modified by genetic polymorphisms in class I alcohol dehydrogenases ADH1B and ADH1C, and glutathione-S-transferases GSTM1 and GSTT1. Pharmacogenetics 13: 225-230, 2003.
76. Unal M, Tamer L, Ates NA, et al: Glutathione S-transferase M1, T1, and P1 gene polymorphism in laryngeal squamous cell carcinoma. Am J Otolaryngol 25: 318-322, 2004.
77. Sikdar N, Paul RR and Roy B: Glutathione S-transferase M3 (A/A) genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers. Int J Cancer 109: 95-101, 2004.
78. Gaudet MM, Olshan AF, Poole C, Weissler MC, Watson M and Bell DA: Diet, GSTM1 and GSTT1 and head and neck cancer. Carcinogenesis 25: 735-740, 2004.
79. Drummond SN, De Marco L, Noronha JCM and Gomez RS: GSTM1 polymorphism and oral squamous cell carcinoma. Oral Oncol 40: 52-55, 2004.
80. Majumder M, Sikdar N, Paul RR and Roy B: Increased risk of oral leukoplakia and cancer among mixed tobacco users carrying XRCC1 variant haplotypes and cancer among smokers carrying two risk genotypes: one of each of two loci, GSTM3 and XRCC1 (codon 280). Cancer Epidemiol Biomarkers Prev 14: 2106-2112, 2005.
81. Tiwawech D, Srivatanakul P, Karalak A and Ishida T: Glutathione S-transferase M1 gene polymorphism in Thai nasopharyngeal carcinoma. Asian Pac J Cancer Prev 6: 270-275, 2005.
82. Oude Ophuis M, Manni JJ and Peters WHM: Glutathione S-transferase T1 null polymorphism and the risk for head and neck cancer. Acta Otolaryngol 126: 311-317, 2006.
83. Sharma A, Mishra A, Das BC, Sardana S and Sharma JK: Genetic polymorphism at GSTM1 and GSTT1 gene loci and susceptibility to oral cancer. Neoplasma 53: 309-315, 2006.
84. Peters ES, McClean MD, Marsit CJ, Luckett B and Kelsey KT: Glutathione S-transferase polymorphisms and the synergy of alcohol and tobacco in oral, pharyngeal, and laryngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15: 2196-2202, 2006.
85. Acar H, Ozturk K, Muslumanoglu MH, Yildirim MS, Cora T, Cilingir O and Ozer B: Relation of glutathione S-transferase genotypes (GSTM1 and GSTT1) to laryngeal squamous cell carcinoma risk. Cancer Genet Cytogenet 169: 89-93, 2006.
86. Capoluongo E, Almadori G, Concolino P, et al: GSTT1 and GSTM1 allelic polymorphisms in head and neck cancer patients from Italian Lazio region. Clin Chem Acta 376: 174-178, 2007.
87. Jourenkova-Minorova N, Voho A, Bouchardy C, Wikman H, Dayer P, Benhamou S and Hirvonen A: Glutathione S-transferase GSTM3 and GSTP1 genotypes and larynx cancer risk. Cancer Epidemiol Biomarkers Prev 8: 185-188, 1999.
88. Matthias C, Bockmuhl U, Jahnke V, et al: The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics 8: 1-6, 1998.
89. Park JY, Schantz SP, Stern JC, Kaur T and Lazarus P: Association between glutathione S-transferase π genetic polymorohisms and oral cancer risk. Pharmacogenetics 9: 497-504, 1999.
90. Katoh T, Kaneko S, Takasawa S, et al: Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. Pharmacogenetics 9: 165-169, 1999.
91. Kelders WPA, Oude Ophuis MB, Roelofs HMJ, Peters WHM and Manni JJ: The association between glutathione S-transferase P1 genotype and plasma level in head and neck. Laryngoscope 112: 462-466, 2002.
92. Amador AG, Righi PD, Radpour S, et al: Polymorphisms of xenobiotic metabolizing genes in oropharyngeal carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93: 440-445, 2002.
93. Oude Ophuis MB, Roelofs HNJ, van den Brandt PA, Peters WHM and Manni JJ: Polymorphisms of the glutathione S-transferase P1 gene and head and neck cancer susceptibility. Head Neck 25: 37-43, 2003.
94. Cho CG, Lee SK, Nam SY, et al: Association of the GSTP1 and NQO1 polymorphisms and head and neck squamous cell carcinoma risk. J Korean Med Sci 21: 1075-1079, 2006.
95. Hamel N, Karimi S, Hebert-Blouin MN, et al: Increased risk of head and neck cancer in association with GSTT1 nullizygosity for individuals with low exposure to tobacco. Int J Cancer 87: 452-454, 2000.
96. Drummond SN, Gomez RS, Noronha JCM, Pordeus IA, Barbosa AA and De Marco L: Association between GSTT-1 gene deletion and the susceptibility to oral squamous cell carcinoma in cigarette-smoking subjects. Oral Oncol 41: 515-519, 2005.
97. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K and Bell DA: A pilot study testing the association between N-acetyl-transferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 19: 1803-1807, 1998.
98. Jourenkova-Mironova N, Wikman H, Bouchardy C, Mitrunen K, Dayer P, Benhamou S and Hirovonen A: Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers. Pharmacogenetics 9: 533-537, 1999.
99. Fronhoffs S, Bruning T, Ortiz-Pallardo E, et al: Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, * 10, * 11, * 14 and * 17 polymorphism in squamous cell cancer of head and neck. Carcinogenesis 22: 1405-1412, 2001.
100. Varzim G, Monteiro E, Siva R, Pinheiro C and Lopes C: Polymorphisms of arylamine N-acetyltransferase (NAT1 and NAT2) and larynx cancer susceptibility. ORL 64: 206-212, 2002.
101. Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL and Schwarts SM: N-acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk. Carcinogenesis 22: 1993-1999, 2001.
102. Unal M, Tamer L, Akbas Y, Pata YS, Vayisoglu Y, Degirmenci U and Camdeviren H: Genetic polymorphism of N-acetyltransferase 2 in the susceptibility to laryngeal squamous cell carcinoma. Head Neck 27: 1056-1060, 2005.
103. Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer P, Benhamou S and Hirvonen A: High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res 60: 534-536, 2000.
104. Wenghoefer M, Pesch B, Harth V, et al: Association between head and neck cancer and microsomal epoxide hydrolase genotypes. Arch Toxicol 77: 37-41,2003.
105. Park JY, Schants SP and Lazarus P: Epoxide hydrolase genotype and oropharyngeal cancer risk: interaction with GSTM1 genotype. Oral Oncol 39: 483-490, 2003.
106. Begleiter A, Norman A, Leitao D, et al: Role of NQO1 polymorphisms as risk factors for squamous cell carcinoma of the head and neck. Oral Oncol 41: 927-933, 2005.
107. Hirankarn N, Kimkong I and Mutirangura A: HLA-E polymorphism in patients with nasopharyngeal carcinoma. Tissue Antigens 64: 588-592, 2004.
108. Elahi A, Bendaly J, Zheng Z, Muscat JE, Richie JP, Schantz SP and Lazarus P: Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 98: 872-880, 2003.
109. Zheng Z, Park JY, Guillemette C, Schantz SP and Lazarus P: Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst 93: 1411-1418, 2001.
110. Boccia S, Cadoni G, La Torre G, et al: A case-control study investigating the role of sulfotransferase 1A1 polymorphism in head and neck cancer. J Cancer Res Clin Oncol 132: 466-472, 2006.
111. Harty LC, Caporaso NE, Hayes RB, et al. Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. J Natl Cancer Inst 89: 1968-1975, 1997.
112. Olshan AF, Weissler MC, Watson MA and Bell DA: Risk of head and neck cancer and the alcohol dehydrogenase 3 genotype. Carcinogenesis 22: 57-61, 2001.
113. Sturgis EM, Dahlstrom KR, Guan Y, Eicher SA, Strom SS, Spitz MR and Wei Q: Alcohol dehydrogenase 3 genotype is not associated with risk of squamous cell carcinoma of the oral cavity and pharynx. Cancer Epidemiol Biomarkers Prev 10: 273-275, 2001.
114. Schwarts SM, Doody DR, Fitzgibbons ED, Ricks S, Porter PL and Chen C: Oral squamous cell cancer risk in relation to alcohol consumption and alcohol dehydrogenase-3 genotypes. Cancer Epidemiol Biomarkers Prev 10: 1137-1144, 2001.
115. Zavras AI, Wu T, Laskaris G, et al: Interaction between a single nucleotide polymorphism in the alcohol dehydrogenase 3 gene, alcohol consumption and oral cancer risk. Int J Cancer 97: 526-530, 2002.
116. Nishimoto IN, Pinheiro NA, Rogatto SR, et al: Alcohol dehydrogenase 3 genotype as a risk factor for upper aerodigestive tract cancers. Arch Otolaryngol Head Neck Surg 130: 78-82, 2004.
117. Yokoyama A, Muramatsu T, Ohmori T, et al: Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics. Carcinogenesis 19: 1383-1387, 1998.
118. Yokoyama A, Muramatsu T, Ohmori T, et al: Alcohol and aldehyde dehydrogenase gene polymorphisms and oropharyngolaryngeal, esophageal and stomach cancers in Japanese alcoholics. Carcinogenesis 22: 433-439, 2001.
119. Hashimoto T, Uchida K, Okayama N, et al: ALDH2 1510 G/A (Glu487Lys) polymorphism interaction with age in head and neck squamous cell carcinoma. Tumor Biol 27: 334-338, 2006.
120. Asakage T, Yokoyama A, Haneda T, et al: Genetic polymorphisms of alcohol and aldehyde dehydrogenases, and drinking, smoking and diet in Japanese men with oral and pharyngeal squamous cell carcinoma. Carcinogenesis 28: 865-874, 2007.
121. Visapaa JP, Gotte K, Benesova M, et al: Increased cancer risk in heavy drinkers with the alcohol dehydrogenase 1C*1 allele, possibly due to salivary acetaldehyde. Gut 53: 871-876, 2004.
122. Peters ES, McClean MD, Liu M, Eisen EA, Mueller N and Kelsey KT: The ADH1C polymorphism modifies the risk of squamous cell carcinoma of the head and neck associated with alcohol and tobacco use. Cancer Epidemiol Biomarkers Prev 14: 476-482, 2005.
123. Homann N, Stickel F, Konig IR, et al: Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int J Cancer 118: 1998-2002, 2006.
124. Weinstein SJ, Gridley G, Harty LC, et al: Folate intake, serum homocysteine and methylenetetrahydrofolate reductase (MTHFR) C677T genotype are not associated with oral cancer risk in Puerto Rico. J Nutr 132: 762-767, 2002.
125. Neumann AS, Lyons HJ, Shen H, et al: Methylenetetrahydrofolate reductase polymorphisms and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Int J Cancer 115: 131-136, 2005.
126. Capaccio P, Ottaviani F, Cuccarini V, Cenzuales S, Cesana BM and Pignataro L: Association between methylenetetrahydrofolate reductase polymorphisms, alcohol intake and oropharyngolaryngeal carcinoma in northern Italy. J Laryngol Otol 119: 371-376, 2005.
127. Vairaktaris E, Yapijakis C, Kessler P, et al: Methylenetetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer. J Cancer Res Clin Oncol 132: 219-222, 2006.
128. Zhang Z, Shi Q, Sturgis EM, Spitz MR and Wei Q: Polymorphisms and haplotypes of serine hydroxymethyl-transferase and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Phamacogenet Genomics 15: 557-564, 2005.
129. Zhang Z, Shi Q, Liu Z, Sturgis EM, Spitz MR and Wei Q: Polymorphisms of methionine synthase and methionine synthase reductase and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Cancer Epidemiol Biomarkers Prev 14: 1188-1193, 2005.
130. Zhang Z, Shi Q, Sturgis EM, Spitz MR, Hong WK and Wei Q: Thymidylate synthase 5′- and 3′-untranslated region polymorphisms associated with risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 10: 7903-7910, 2004.
131. Vairaktaris E, Yapijakis C, Wiltfang J, et al: Are Factor V and prothrombin mutations associated with increased risk of oral cancer? Anticancer Res 25: 2561-2256, 2005.
132. Olshan AF, Watson MA, Weissler MC and Bell DA: XRCC1 polymorphisms and head and neck cancer. Cancer Lett 178: 181-186, 2002.
133. Tae K, Lee HS, Park BJ, et al: Association of DNA repair gene XRCC1 polymorphisms with head and neck cancer in Korean population. Int J Cancer 111: 805-808, 2004.
134. Demokan S, Demir D, Suoglu Y, Kiyak E, Akar U and Dalay N: Polymorphisms of the XRCC1 repair gene in head and neck cancer. Pathol Oncol Res 11: 22-25, 2005.
135. Cao Y, Miao XP, Huang MY, et al: Polymorphisms of XRCC1 genes and risk of nasopharyngeal carcinoma in the Cantonese population. BMC Cancer 6: 167, 2006.
136. Ramachandran S, Ramadas K, Hariharan R, Kumar RR and Pillai MR: Single nucleotide polymorphisms of DNA repair genes XRCC1 and XPD and its molecular mapping in Indian oral cancer. Oral Oncol 42: 350-362, 2006.
137. Kietthubthew S, Sriplung H, Au WW and Ishida T: Polymorphism in DNA repair genes and oral squamous cell carcinoma in Thailand. Int J Hyg Environ Health 209: 21-29, 2006.
138. Majumder M, Sikdar N, Ghosh S and Roy B: Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Int J Cancer 120: 2148-2156, 2007.
139. Cho EY, Hildesheim A, Chen CJ, et al: Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. Cancer Epidemiol Biomarkers Prev 12: 1100-1104, 2003.
140. Huang WY, Olshan AF, Schwarts SM, et al: Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev 14: 1747-1753, 2005.
141. Sturgis EM, Castillo EJ, Li L, et al: Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis 20: 2125-2129, 1999.
142. Gajecka M, Rydzanicz M, Jaskula-Sztul R, Wierzbicka M, Szyfter W and Szyfter K: Reduced DNA repair capacity in laryngeal cancer subjects. Adv Otorhinolaryngol 62: 25-37, 2005.
143. Benhamou S, Tuimala J, Bouchardy C, Dayer P, Sarasin A and Hirvonen A: DNA repair gene XRCC2 and XRCC3 polymorphisms and susceptibility to cancers of the upper aerodigestive tract. Int J Cancer 112: 901-904, 2004.
144. Shen H, Sturgis EM, Dahlstrom KR, Zheng Y, Spitz MR and Wei Q: A variant of the DNA repair gene XRCC3 and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Int J Cancer 99: 869-872, 2002.
145. Sturgis EM, Zheng R, Li L, et al: XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis 21: 2219-2223, 2000.
146. Sturgis EM, Castillo EJ, Li L, Eicher SA, Strom SS, Spitz MR and Wei Q: XPD/ERCC2 exon 8 polymorphisms: rarity and lack of significance in risk of squamous cell carcinoma of the head and neck. Oral Oncol 38: 475-477, 2002.
147. Sturgis EM, Dahlstrom KR, Spitz MR and Wei Q: DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 128: 1084-1088, 2002.
148. Cui Y, Morgenstern H, Greenland S, et al: Polymorphism of xeroderma pigmentosum group G and the risk of lung cancer and squamous cell carcinomas of the oropharynx, larynx, and esophagus. Int J Cancer 118: 714-720, 2006.
149. Shen H, Sturgis EM, Khan SG, et al: An intoronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Res 61: 3321-3325, 2001.
150. Yang M, Kang MJ, Choi Y, et al: Associations between XPC expression, genotype, and the risk of head and neck cancer. Environ Mol Mutagen 45: 374-379, 2005.
151. Elahi A, Zheng Z, Park J, Eyring K, McCaffrey T and Lazarus P: The human OGG1 DNA repair enzyme and its association with orolaryngeal cancer risk. Carcinogenesis 23: 1229-1234, 2002.
152. 326Cys polymorphism and risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers Prev 13: 1081-1083, 2004.
153. Lu J, Wang LE, Xiong P, Sturgis E, Spitz MR and Wei Q: 172G>T variant in the 5′ untranslated region of DNA repair gene RAD51 reduces risk of squamous cell carcinoma of the head and neck and interacts wirth a P53 codon 72 variant. Carcinogenesis 28: 988-994, 2007.
154. Birgander R, Sjalander A, Zhou Z, Fan C, Beckman L and Beckman G: p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered 46: 49-54, 1996.
155. Yung WCW, Ng MH, Sham JST and Choy DTK: p53 codon 72 polymorphism in nasopharyngeal carcinoma. Cancer Genet Cytogenet 93: 181-182, 1997.
156. Golovleva I, Birgander R, Sjalander A, Lundgren E and Beckman L: Interferon-α and P53 alleles involved in nasopharyngeal carcinoma. Carcinogenesis 18: 645-649, 1997.
157. Hamel N, Black MJ, Ghadirian P and Foulkes WD: No association between p53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer 82: 757-759, 2000.
158. Summersgill KF, Smith EM, Kirchner HL, Haugen TH and Turek LP: p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90: 334-339, 2000.
159. Tandle AT, Sanghvi V and Saranath D: Determination of p53 genotypes in oral cancer patients from India. Br J Cancer 84: 739-742, 2001.
160. Sourvinos G, Rizos E and Spandidos DA: p53 codon 72 polymorphism is linked to the development and not the progression of benign and malignant laryngeal tumours. Oral Oncol 37: 572-578, 2001.
161. Shen H, Zheng Y, Sturgis EM, Spitz MR and Wei Q: P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 183: 123-130, 2002.
162. Drummond SN, De Marco L, Pordeus IDA, Barbosa AA and Gomez RS: TP53 codon 72 polymorphism in oral squamouos cell carcinoma. Anticancer Res 22: 3379-3382, 2002.
163. Nagpal JK, Patnaik S and Das BR: Prevalence of high-risk human papilloma virus types and its association with p53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of Eastern India. Int J Cancer 97: 649-653, 2002.
164. Tiwawech D, Srivantanakul P, Karaluk A and Ishida T: The p53 codon 72 polymorphism in Thai nasopharyngeal carcinoma. Cancer Lett 198: 69-75, 2003.
165. Kietthubthew S, Sriplung H, Au WW and Ishida T: The p53 codon 72 polymorphism and risk of oral cancer in Southern Thailand. Asian Pac J Cancer Prev 4: 209-214, 2003.
166. Katiyar S, Thelma BK, Murthy NS, et al: Polymorphism of the p53 codon 72 arg/pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell Biochem 252: 117-124, 2003.
167. Cortezzi SS, Provazzi PJ, Sobrinho JS, et al: Analysis of human papillomavirus prevalence and TP53 polymorphism in head and neck squamous cell carcinomas. Cancer Genet Cytogenet 150: 44-49, 2004.
168. Scheckenback K, Lieven O, Gotte K, Bockmuhl U, Zots R, Bier H and Balz V: p53 codon 72 polymorphic variants, loss of allele-specific transcription, and human papilloma virus 16 and/or 18 E6 messenger RNA expression in squamous cell carcinomas of the head and neck. Cancer Epidemiol Biomarkers Prev 13: 1805-1809, 2004.
169. Twu CW, Jiang RS, Shu CH and Lin JC: Association of p53 codon 72 polymorphism with risk of hypopharyngeal sqaumous cell carcinoma in Taiwan. J Formos Med Assoc 105: 99-104, 2006.
170. Sousa H, Santos AM, Catarino R, et al: Linkage of TP53 codon 72 pro/pro genotype as predictive factor for nasopharyngeal carcinoma development. Eur J Cancer Prev 15: 362-366, 2006.
171. Perrone F, Mariani L, Pastore E, et al: p53 codon 72 polymorphisms in human papillomavirus-negative and papillo-mavirus-positive squamous cell carcinomas of the oropharynx. Cancer 109: 2461-2465, 2007.
172. Zheng Y, Shen H, Sturgis EM, et al: Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis 22: 1195-1199, 2001.
173. Deng L, Zhao XR, Pan KF, Wang Y, Deng XY, Lu YY and Cao Y: Cyclin D1 polymorphism and susceptibility to NPC using DHPLC. Acta Biochem Biophys Sinica 34: 16-20, 2002.
174. Wong YK, Lin SC, Chang CS, Tseng YH, Liu CJ, Lin HC and Chang KW: Cyclin D1 genotype in areca-associated oral squamous cell carcinoma. J Oral Pathol Med 32: 265-270, 2003.
175. Nishimoto IN, Pinheiro NA, Rogatto SR, Carvalho AL, Simpson AJ, Carballero OL and Kowalski LP: Cyclin D1 gene polymorphism as a risk factor for squamous cell carcinoma of the upper aerodigestive system in non-alcoholics. Oral Oncol 40: 604-610, 2004.
176. Monteiro E, Varzim G, Pires AM, Teixeira M and Lopes C: Cyclin D1 A870G polymorphism and amplification in laryngeal squamous cell carcinoma: implications of tumor localization and tobacco exposure. Cancer Detect Prev 28: 237-243, 2004.
177. Holley SL, Matthias C, Jahnke V, Fryer AA, Strange RC and Hoban PR: Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma. Oral Oncol 41: 156-160, 2005.
178. Rydzanicz M, Golusinski P, Mielcarek-Kuchta D, Golusinski W and Szyfter K: Cyclin-D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx. Eur Arch Otorhinolaryngol 263: 43-48, 2006.
179. Catarino RJ, Breda E, Coelho V, Pinto D, Sousa H, Lopes C and Medeiros R: Association of the A870G cyclin D1 gene polymorphism with genetic susceptibility to nasopharyngeal carcinoma. Head Neck 28: 603-608, 2006.
180. Sathyan KM, Nalinakumari KR, Abraham T and Kannan S: Influence of single nucleotide polymorphisms in H-Ras and cyclin D1 genes on oral cancer susceptibility. Oral Oncol 42: 607-613, 2006.
181. Rodrigues FCC, Kawasaki-Oyama RS, Fo JFG, et al: Analysis of CDKN1A polymorphisms: markers of cancer susceptibility? Cancer Genet Cytogenet 142: 92-98, 2003.
182. Li G, Liu Z, Sturgis EM, Shi Q, Chamberlain RM, Spitz MR and Wei Q: Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 26: 1596-1602, 2005.
183. waf1/Cip1 cyclin-dependent kinase inhibitor gene and human oral cancer. Clin Cancer Res 6: 2440-2447, 2000.
184. ser_arg polymorphism of the WAF-1/C1P-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol Biomarkers Prev 4: 261-267, 1995.
185. Cip1 cyclin-dependent kinase inhibitor gene. Cancer 79: 2424-2429, 1997.
186. Tsai MH, Chen WC and Tsai FJ: Correlation of p21 gene codon 31 polymorphism and TNF-α gene polymorphism with nasopharyngeal carcinoma. J Clin Lab Anal 16: 146-150, 2002.
187. He Y, Zhou G, Zhai Y, Dong X, Lv L, He F and Yao K: Association of PLUNC gene polymorphisms with susceptibility to nasopharyngeal carcinoma in a Chinese population. J Med Genet 42: 172-176, 2005.
188. Zheng Y, Shen H, Sturgis EM, Wang LE, Shete S, Spitz MR and Wei Q: Haplotypes of two variants in p16 (CDKN2/MTS-1/INK4a) exons 3 and risk of squamous cell carcinomoa of the head and neck: a case-control study. Cancer Epidemiol Biomarkers Prev 11: 640-645, 2002.
189. Li G, Sturgis EM, Wang LE, et al: Association between the V109G polymorphism of the p27 gene and the risk and progression of oal squamous cell carcinoma. Clin Cancer Res 10: 3996-4002, 2004.
190. Li G, Sturgis EM, Wang LE, et al: Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. Carcinogenesis 25: 1911-1916, 2004.
191. Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, et al: The MDM2 promoter polymorpism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42: 694-698, 2005.
192. Duh FM, Fivash M, Moody M, et al: Characterization of new SNP c767A/T (Arg222Trp) in the candidate TSG FUS2 on human chromosome 3p21.3: prevalence in Asian populations and analysis of association with nasopharyngeal cancer. Mol Cell Probes 18: 39-44, 2004.
193. Zheng Y, Li L, Shen H, et al: Polymorphic hCHK2/hCds1 codon 84 allele and risk of squamous cell carcinoma of the head and neck - a case-control analysis. Carcinogenesis 22: 2005-2008, 2001.
194. Zinzindohoue F, Blons H, Hans S, et al: Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head neck squamous cell carcinoma. Anticancer Res 24: 2021-2026, 2004.
195. Hashimoto T, Uchida K, Okayama N, et al: Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett 211: 19-24, 2004.
196. Lin SC, Chung MY, Huang JW, Shieh TM, Liu CJ and Chang KW: Correlation between functional genotypes in the matrix metalloproteinases-1 promoter and risk of oral squamous cell carcinomas. J Oral Pathol Med 33: 323-326, 2004.
197. Cao ZG and Li CZ: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances oral squamous cell carcinoma susceptibility in a Chinese population. Oral Oncol 42: 32-38, 2006.
198. O-charoenrat P, Leksrisakul P and Sangruchi S: A functional polymorphism in the matrix metalloproteinase-1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer. Int J Cancer 118: 2548-2553, 2006.
199. Vairaktaris E, Yapijalis C, Derka S, et al: Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma. Anticancer Res 27: 459-464, 2007.
200. Lin SC, Lo SS, Liu CJ, Chung MY, Huang JW and Chang KW: Functional genotyoe in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med 33: 405-409, 2004.
201. O-charoenrat P and Khantapura P: The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol 42: 257-267, 2006.
202. Vairaktaris E, Yapijakis C, Yiannopulos A, et al: Strong association of the tissue inhibitor of metalloproteinase-2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol Rep 17: 963-968, 2007.
203. Vairaktaris E, Yapijakis C, Derka S, et al: Association of platelet glycoprotein Ia polymorphism with minor increase of risk for oral cancer. Eur J Surg Oncol 32: 455-457, 2006.
204. Tsai MH, Chen WC, Chen HY and Tsai FJ: Urokinase gene 3′-UTR T/C polymorphism is associated with oral cancer. J Clin Lab Anal 18: 276-279, 2004.
205. Zhang Z, Wang LE, Sturgis EM, et al: Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12: 5596-5602, 2006.
206. Jrad BBH, Mahfouth W, Bouaouina N, et al: A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction. Cancer Lett 233: 21-27, 2006.
207. Fisher MJ, Virmani AK, Wu L, et al: Nucleotide substitution in the ectodomain of TRAIL receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 7: 1688-1697, 2001.
208. Teng MS, Brandwein-Gensler MS, Teixeira MS, Martignetti JA and Duffey DC: A study of TRAIL receptors in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 131: 407-412, 2005.
209. Jalbout M, Bouaouina N, Gargouri J, Corbex M, Ahmed SB and Chouchane L: Polymorphism of the stress protein HSP70-2 gene is associated with the susceptibility to the nasopharyngeal carcinoma. Cancer Lett 193: 75-81,2003.
210. Liu CJ, Wong YK, Chang KW, Chang HC, Liu HF and Lee YJ: Tumor necrosis factor-α promoter polymorphism is associated with susceptibility to oral squamous cell carcinoma. J Oral Pathol Med 34: 608-612, 2005.
211. Ho SY, Wang YJ, Huang PC, et al: Evaluation of the associations between the single nucleotide polymorphisms of the promoter region of the tumor necrosis factor-α gene and nasopharyngeal carcinoma. J Chin Med Assoc 69: 351-357, 2006.
212. Campa D, Hashibe M, Zaridze D, et al: Association of common polymorphisms in inflammatory genes with risk of developing cancers of the upper aerodigestive tract. Cancer Causes Control 18: 449-455, 2007.
213. Tsai MH, Chen WC, Tsai CH, Hang LW and Tsai FJ: Interleukin-4 gene, but not the interluekin-1 beta gene polymorphism, is associated with oral cancer. J Clin Lab Anal 19: 93-98, 2005.
214. Vairaktaris E, Yapijakis C, Serefoglou Z, et al: The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 33: 504-507, 2007.
215. Pratesi C, Bortolin MT, Bidoli E, et al: Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55: 23-30, 2006.
216. Vairaktaris E, Yiannopoulos A, Vylliotis A, et al: Strong association of interleukin-6 -174 G>C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 21: 246-250, 2006.
217. Zhou XX, Jia WH, Shen GP, et al: Sequence variants in toll-like receptor 10 are associated with nasopharyngeal carcinoma risk. Cancer Epidemiol Biomarkers Prev 15: 862-866, 2006.
218. Hirunsatit R, Kongruttanachok N, Shotelersuk K, Supiyaphun P, Voravud N, Sakuntabhai A and Mutirangura A: Polymeric immunoglobulin receptor polymorphisms and risk of nasopharyngeal cancer. BMC Genet 4: 3, 2003.
219. Cascorbi I, Henning S, Brockmoller J,et al: Substantially reduced risk of cancer of the aerodigestive tract in subjects with variants-463A of the myeloperoxidase gene. Cancer Res 60: 644-649, 2000.
220. Lin SC, Liu Cj, Yeh WI, Lui MT, Chang KW and Chang CS: Functional polymorphism in NF-κB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett 243: 47-54, 2006.
221. Degerli N, Yilmaz E and Bardakci F: The δ32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin Biochem 38: 248-252, 2005.
222. Wong YK, Chang KW, Cheng CY and Liu CJ: Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. J Oral Pathol Med 35: 51-54, 2006.
223. Ren W, Zheng H, Li M, et al: A functional single nucleotide polymorphism site detected in nasopharyngeal carcinoma-associated transforming gene Tx. Cancer Genet Cytogenet 157: 49-52, 2005.
224. Kang D, Gridley G, Huang WY, et al: Microsatellite polymorphisms in the epidermal growth factor receptor (EGFR) gene and the transforming growth factor-α (TGFA) gene and risk of oral cancer in Puerto Rico. Phamacogenet Genomics 15: 343-347, 2005.
225. Kaur R, Nagpal JK and Das BR: Polymorphism in IGF-2 as a surrogate marker for predisposition towards tobacco chewing-mediated oral cancer. Tumor Biol 26: 147-152, 2005.
226. Zarvas AI, Pitiphat W, Wu T, Cartsos V, Lam A, Douglass CW and Diehl SR: Insulin-like growth factor II receptor gene-167 genotype increases the risk of oral squamous cell carcinoma in humans. Cancer Res 63: 296-297, 2003.
227. Wei YS, Zhu YH, Du B, et al: Association of transforming growth factor-beta1 gene polymorphisms with genetic susceptibility to nasopharyngeal carcinoma. Clin Chim Acta 380: 165-169, 2007.
228. Ku KT, Wan L, Peng HC, Tsai MH, Tsai CH and Tsai FJ: Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer. Oral Oncol 41: 497-502, 2005.
229. Liu Z, Calderon JI, Zhang Z, Sturgis EM, Spitz MR and Wei Q: Polymorphisms of vitamin D receptor gene protect against the risk of head and neck cancer. Phamacogenet Genomics 15: 159-165, 2005.
230. dos Santos ML, Sibov TT, Nishimoto IN, Kowalski LP, Miracca EC and Nagai MA: The CAG repeat polymorphism in the androgen receptor gene (AR) and its relationship to head and neck cancer. Oral Oncol 40: 177-182, 2004.
231. Kureshi N, Ghaffar S, Siddiqui S, Salahuddin I and Frossard PM: Head and neck cancer susceptibility: a genetic marker in the methylenetetrahydrofolate reductase gene. ORL 66: 241-245, 2004.
232. Hashibe M, Brennan P, Strange RC, et al: Meta- and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck canccer. Cancer Epidemiol Biomarkers Prev 12: 1509-1517, 2003.
233. Tripathy CB and Roy N: Meta-analysis of glutathione S-transferase M1 genotype and risk toward head and neck cancer. Head Neck 28: 217-224, 2006.
234. Hu Z, Ma H, Chen F, Wei Q and Shen H: XRCC1 polymorphisms and cancer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev 14: 1810-1818, 2005.
235. Yang CX, Matsuo K, Wang ZM and Tajima K: Phase I/II enzyme gene polymorphisms and esophageal cancer: a meta-analysis of the literature. World J Gastroenterol 11: 2531-2538, 2005.
236. Landi MT, Bertazzi PA, Shields PG, et al: Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 4: 242-246, 1994.
237. Dodd LE, Sengupta S, Chen IH, et al: Genes involved in DNA repair and nitrosamine metabolism and those located on chromosome 14q32 are dysregulated in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15: 2216-2225, 2006.
238. Albano E, Tomasi A, Persson JO, Terelius Y, Goria-Gatti L, Ingelman-Sundberg M and Dianzani MU: Role of ethanol-inducible cytochrome P450 (P450IIE1) in catalysing the free radical activation of aliphatic alcohols. Biochem Pharmacol 41: 1895-1902, 1991.
239. Seidegard J, Pero RW, Miller DG and Beattie EJ: A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis 7: 751-753, 1986.
240. Pemble S, Schroeder KR, Spencer SR, et al: Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300:271-276, 1994.
241. Saadat M: Genetic polymorphisms of glutathione S-transferase T1 (GSTT1) and susceptibility to gastric cancer: a meta-analysis. Cancer Sci 97: 505-509, 2006.
242. Wenzlaff AS, Cote ML, Bock CH, Land SJ and Schwartz AG: GSTM1, GSTT1 and GSTP1 polymorphisms, environmental tobacco smoke exposure and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 26: 395-401, 2005.
243. Nakajima T, Wang RS, Nimura Y, et al: Expression of cytochrome P450s and glutathione S-transferase in human esophagus with squamous cell carcinomas. Carcinogenesis 17: 1477-1481, 1996.
244. Berhane K, Widersten M, Engstrom A, Kozarich JW and Mannervik B: Detoxication of base propenals and other alpha, beta-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases. Proc Natl Acad Sci USA 91: 1480-1484, 1994.
245. Hein DW, Doll MA, Fretland AJ, et al: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9: 29-42, 2000.
246. Hassett C, Aicher L, Sidhu JS and Omiecinski CJ: Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 3: 421-428, 1994.
247. Harrison DJ, Hubbard AL, MacMillan J, Wyllie AH and Smith CA: Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer. Br J Cancer 79: 168-171, 1999.
248. Wu X, Gwyn K, Amos CI, Makan N, Hong WK and Spitz MR: The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African-Americans and Mexican-Americans. Carcinogenesis 22: 923-928, 2001.
249. Lancaster JM, Brownlee HA, Bell DA, et al: Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog 17: 160-162, 1996.
250. Matsuo K, Wakai K, Hirose K, Ito H, Saito T and Tajima K: Alcohol dehydrogenase 2 His47Arg polymorphism influences drinking habit independently of aldehyde dehydrogenase 2 Glu487Lys polymorphism: analysis of 2,299 Japanese subjects. Cancer Epidemiol Biomarkers Prev 15: 1009-1013, 2006.
251. Lee HC, Lee HS, Jung SH, Yi SY, Jung HK, Yoon JH and Kim CY: Association between polymorphisms of ethanol-metabolizing enzymes and susceptibility to alcoholic cirrhosis in a Korean male population. J Korean Med Sci 16: 745-750, 2001.
252. 4 compounds such as diacetyl, acetoin, and 2,3-butanediol in normal male students after ethanol ingestion. Alcohol 17: 119-124, 1999.
253. Tiemersma EW, Wark PA, Ocke MC, Bunschoten A, Otten MH, Kok FJ and Kampman E: Alcohol consumption, alcohol dehydrogenase 3 polymorphism, and colorectal adenomas. Cancer Epidemiol Biomarkers Prev 12: 419-425, 2003.
254. Thompson LH, Brookman KW, Jones NJ, Allen SA and Carrono AV: Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange. Moll Cell Biol 10: 6160-6171, 1990.
255. Kubota Y, Nash RA, Klungland A, Schar P, Barnes DE and Lindahl T: Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J 15: 6662-6670, 1996.
256. Abdel-Rahman SZ and El-Zein RA: The 399G1n polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 159: 63-71, 2000.
257. Drapkin R, Sancar A and Reinberg D: Where transcription meets repair. Cell 77: 9-12, 1994.
258. Qiao Y, Spitz MR, Shen H, et al: Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 23: 295-299, 2002.
259. Hiyama T, Yokozaki H, Shimamoto F, Haruma K, Yasui W, Kajiyama G and Tahara E: Frequent p53 gene mutations in serrated adenomas of the colorectum. J Pathol 186: 131-139, 1998.
260. Hiyama T, Haruma K, Kitadai Y, et al: Helicobacter pylori eradication therapy for high-grade mucosa-associated lymphoid tissue lymphomas of the stomach with analysis of p53 and K-ras alteration and microsatellite instability. Int J Oncol 18: 1207-1212, 2001.
261. Hiyama T, Tanaka S, Yoshihara M, et al: Chromosomal and microsatelllite instability in sporadic gastric cancer. J Gastroenterol Hepatol 19: 756-760, 2004.
262. Karsai S, Abel U, Roesch-Ely M, et al: Comparison of p16(INK4a) expression with p53 alterations in head and neck cancer by tissue microarray analysis. J Pathol 211: 314-322, 2007.
263. Thomas M, Kalita A, Labrecque S, Pim D, Banks L and Matlashewski G: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19: 1092-1100, 1999.
264. Perez-Ordonez B, Beauchemin M and Jordan RC: Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol 59: 445-453, 2006.
265. Lewis SJ and Smith GD: Alcohol, ALDH2, and esophageal cancer: a meta-analysis which illustrates the potentials and limitations of a Mendelian randomization approach. Cancer Epidemiol Biomarkers Prev 14: 1967-1971, 2005.
266. Hu Y, McDermott MP and Ahrendt SA: The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 11: 2502-2509, 2005.
267. Yi SY and Lee WJ: A p53 genetic polymorphism of gastric cancer: difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol 12: 6536-6539, 2006.
268. Han J, Cox DG, Colditz GA and Hunter DJ: The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US Caucasian women. Mol Carcinog 45: 694-700, 2006.
269. Scherubl H, von Lampe B, Faiss S, et al: Screening for oesophageal neoplasia in patients with head and neck cancer. Br J Cancer 86: 239-243, 2002.
270. Hashimoto CL, Iriya K, Baba ER, et al: Lugol's dye spray chromoendoscopy establishes early diagnosis of esophageal cancer in patients with primary head and neck cancer. Am J Gastroenterol 100: 275-282, 2005.
271. Hall IP and Blakey JD: Genetic association studies in Thorax. Thorax 60: 357-359, 2005.
272. Gauderman WJ: Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 21: 35-50, 2002.
273. Purcell S, Cherny SS and Sham PC: Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19: 149-150, 2003.
274. Hoover RN: Cancer-nature, nurture, or both. N Engl J Med 343: 135-136, 2000.